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In the last 2 decades, various biologic agents have
been developed to treat autoimmune disorders.
Along with their high clinical efficacy, these agents
have been associated with several paradoxical
proinflammatory or autoimmune reactions, such as
autoimmune hepatitis, drug-induced lupus erythe-
matosus, psoriasiform eruptions, and alopecia areata
(AA). New cases of AA become more frequent in
patients undergoing treatment with biologic thera-
pies, especially antietumor necrosis factor (TNF)-
alpha agents, including infliximab, adalimumab, and
etanercept.1 Development of AA also has been noted
with other biologic agents such as efalizumab,
ustekinumab, and daclizumab.2-4 Denosumab is a
new biologic agent that suppresses osteoclast-
mediated bone resorption. This agent was recently
approved by the US Food and Drug Administration
for treatment of osteoporosis in postmenopausal
women at high risk of fracture and prevention of
skeletal-related events in patients with bone metas-
tases and unresectable giant cell tumors. Denosumab
is a fully human monoclonal antibody to receptor
activator of nuclear factor kappa b ligand (RANKL)
that belongs to a group of anti-TNF agents. We
describe a case of extensive AA after treatment with
denosumab.CASE REPORT
A 69-year-old white man was referred for rapidly
progressive hair loss of 2 weeks’ duration. The
patient’s medical history included vitamin B12 defi-
ciency, psoriasis with mainly scalp involvement, and
severe osteoporosis caused by renal phosphate leak
along with the family history of severe osteoporosis.the Department of Dermatology, Chaim Sheba Medical
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rosis with bisphosphonates, calcium, and vitamin D
and an increased risk for fractures, subcutaneous
injection of denosumab at a dose of 60 mg was
administered. About 2 weeks after receiving the
denosumab, the patient had rapidly progressive
nonscarring patchy hair loss with clinical and dermo-
scopic features of AA,which resultedwithin 2months
in alopecia universalis (Fig 1). There was no nail
involvement. Simultaneously, scalp psoriasis re-
gressed. The patient denied family or personal history
of AA and didn’t report any recent infection, vaccina-
tion, or stress. Complete blood count and blood
chemistry results were normal, and antinuclear anti-
bodies were negative. Histopathology of the scalp
found features of AA on the background of psoriasi-
form epidermal hyperplasia (Fig 2). Treatment was
started with a daily application of betamethasone
valerate 0.1% solution in combination with topical
5% minoxidil solution. On follow-up after 10 months,
the patient had only minimal vellus hair regrowth.
DISCUSSION
The TNF-family molecule RANKL and its receptor
RANK (receptor activator of nuclear factor kappa)
were originally identified as key regulators of bone
remodeling and are essential for the differentiation,JAAD Case Reports 2016;2:298-300.
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Fig 1. A, Extensive AA 2 weeks after denosumab injection. B, Two months after denosumab
treatment, AA universalis.
Fig 2. Histopathology of the scalp. A, Psoriasiform epidermal hyperplasia, focal thinning of the
superpapillary plate, dilated dermal papillae containing tortious blood vessel capillaries,
perifollicular and perivascular lymphocytic infiltrate. Most hair follicles are in the catagen/
telogen phase and miniaturized. B, Peribulbar lymphocytic infiltrate. (A and B, Hematoxylin-
eosin stain.)
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in RANK or RANKL display increased bone density
owing to reduced osteoclast formation, whereas the
loss of the RANKL decoy receptor osteoprotegerin
results in lower bone mass caused by unchecked
RANK activation.5,6 Denosumab is a fully human
monoclonal antibody to RANKL that belongs to a
group of anti-TNF agents. Our case describes a
patient that had AA shortly after treatment with
denosumab and, therefore, raises the possibility of
the relationship to this drug. The patient had noprevious personal or family history of AA. However,
the presence of other autoimmune diseases, such as
psoriasis and B12 deficiency, are known to be risk
factors for an additional autoimmune disease.
We suggest 2 possible mechanisms of the devel-
opment of AA after the administration of denosu-
mab. First, as a member of TNF/TNF receptor
superfamily, denosumab bears homology to TNF-a
and therefore may cause paradoxical autoimmune
reaction similar to those reported after using several
TNF-a inhibitors. In addition to a role in controlling
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been recognized as regulators of T-cell/dendritic
cell communications, lymph node formation, and
epithelial cell growth and differentiation.7 The inter-
action between the RANKL, RANK, and osteoprote-
gerin plays a crucial role in the formation of
medullary thymic epithelial cells containing nuclear
molecules called autoimmune regulators and estab-
lishing self-tolerance. It was found that lymphocytes
generated without RANKL fail to establish self-
tolerance and cause severe autoimmune pheno-
types.8 A second possible mechanism that could
explain the development of alopecia may be related
to the impact of RANK on epithelial cell growth and
hair cycling. It was found that RANK is expressed by
the hair follicle germ, bulge stem cells, and the
epidermal basal cells and has been recognized for its
role in the renewal of the epidermo-pilosebaceous
unit.9 RANKL is actively transcribed by the hair
follicle at initiation of its anagen, thus, providing a
mechanism for stem cell RANK engagement and
hair-cycle entry. It was found that mice deficient in
RANKL are unable to initiate a new anagen, whereas
transgenic mice overexpressing RANK in the hair
follicle or administration of recombinant RANKL
both trigger epidermal growth and anagen entry.
Perhaps both mechanisms suggested participate
in our case; the autoimmune mechanism led to AA
and the absence of RANK stimulation prevented new
anagen initiation leading to the persistent disease
course. Complete clinical remission of scalp psoria-
sis observed in our case raises a thought about
testing the effect of RANK inhibitors on psoriasis.
According to published records, side effects associ-
ated with denosumab include musculoskeletal pain,
arthralgia, cystitis, and nasopharyngitis. Regarding
the impact of denosumab on hair, in the phase 1 trial
hair loss was observed in 11% of Japanese women
treated for breast cancererelated bone metastases.10
However, the study does not specify the type of hairloss, and all participants received concurrent chemo-
therapy or hormonal therapy. Therefore, hair loss
may not have been related to treatment with
denosumab. So far, we did not find previous reports
of AA after treatment with denosumab. Physicians
treating their patients with different biologic medi-
cations should be aware of potential paradoxical
autoimmune side effects including the development
of AA.
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